S. Jayade

Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes.

J. Schmier, M. Botteman, M. Karimi, 2022, Clinical lymphoma, myeloma & leukemia.

Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment.

J. Schmier, N. Joshi, M. Botteman, 2021, Clinical lymphoma, myeloma & leukemia.

Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey

D. George, M. Botteman, M. Karimi, 2022, Cancer medicine.

Salicylic acid (SA)-eluting bone regeneration scaffolds with interconnected porosity and local and sustained SA release.

K. Uhrich, J. Faig, Weiling Yu, 2017, Journal of biomedical materials research. Part A.